vs
DOCUSIGN, INC.（DOCU）与欧加隆（OGN）财务数据对比。点击上方公司名可切换其他公司
欧加隆的季度营收约是DOCUSIGN, INC.的1.8倍（$1.5B vs $818.4M），DOCUSIGN, INC.净利率更高（10.2% vs 10.0%，领先0.2%），DOCUSIGN, INC.同比增速更快（8.4% vs -3.5%）
DocuSign是总部位于美国加利福尼亚州旧金山的软件企业，为各类机构提供多设备支持的电子协议管理及电子签名相关产品。截至2025年，公司在180个国家拥有约170万客户，其处理的签名符合美国ESIGN法案、欧盟eIDAS法规要求，满足欧盟高级及合格签名标准。
欧加隆是一家总部位于美国新泽西州泽西城的制药企业，核心业务覆盖生殖医学、避孕、精神科、激素替代疗法及麻醉领域的药物研发与生产。公司所有产品均在美国境外生产，同时美国市场贡献了其三分之一的营收。
DOCU vs OGN — 直观对比
营收规模更大
OGN
是对方的1.8倍
$818.4M
营收增速更快
DOCU
高出11.9%
-3.5%
净利率更高
DOCU
高出0.2%
10.0%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $818.4M | $1.5B |
| 净利润 | $83.7M | $146.0M |
| 毛利率 | 79.2% | 53.6% |
| 营业利润率 | 10.4% | — |
| 净利率 | 10.2% | 10.0% |
| 营收同比 | 8.4% | -3.5% |
| 净利润同比 | 34.1% | 67.8% |
| 每股收益（稀释后） | $0.40 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCUOGN
| Q1 26 | — | $1.5B | ||
| Q4 25 | $818.4M | $1.5B | ||
| Q3 25 | $800.6M | $1.6B | ||
| Q2 25 | $763.7M | $1.6B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.6B |
净利润DOCUOGN
| Q1 26 | — | $146.0M | ||
| Q4 25 | $83.7M | $-205.0M | ||
| Q3 25 | $63.0M | $160.0M | ||
| Q2 25 | $72.1M | $145.0M | ||
| Q1 25 | — | $87.0M | ||
| Q4 24 | — | $109.0M | ||
| Q3 24 | — | $359.0M | ||
| Q2 24 | — | $195.0M |
毛利率DOCUOGN
| Q1 26 | — | 53.6% | ||
| Q4 25 | 79.2% | 49.2% | ||
| Q3 25 | 79.3% | 53.5% | ||
| Q2 25 | 79.4% | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% |
营业利润率DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | 10.4% | -9.8% | ||
| Q3 25 | 8.1% | 15.2% | ||
| Q2 25 | 7.9% | 14.4% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 8.1% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | — | 14.6% |
净利率DOCUOGN
| Q1 26 | — | 10.0% | ||
| Q4 25 | 10.2% | -13.6% | ||
| Q3 25 | 7.9% | 10.0% | ||
| Q2 25 | 9.4% | 9.1% | ||
| Q1 25 | — | 5.8% | ||
| Q4 24 | — | 6.8% | ||
| Q3 24 | — | 22.7% | ||
| Q2 24 | — | 12.1% |
每股收益（稀释后）DOCUOGN
| Q1 26 | — | $0.55 | ||
| Q4 25 | $0.40 | $-0.78 | ||
| Q3 25 | $0.30 | $0.61 | ||
| Q2 25 | $0.34 | $0.56 | ||
| Q1 25 | — | $0.33 | ||
| Q4 24 | — | $0.42 | ||
| Q3 24 | — | $1.38 | ||
| Q2 24 | — | $0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $583.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.0B | — |
| 总资产 | $4.0B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | $583.3M | $574.0M | ||
| Q3 25 | $600.0M | $672.0M | ||
| Q2 25 | $657.4M | $599.0M | ||
| Q1 25 | — | $547.0M | ||
| Q4 24 | — | $675.0M | ||
| Q3 24 | — | $763.0M | ||
| Q2 24 | — | $704.0M |
总债务DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | — | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B |
股东权益DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $752.0M | ||
| Q3 25 | $2.0B | $906.0M | ||
| Q2 25 | $2.0B | $733.0M | ||
| Q1 25 | — | $542.0M | ||
| Q4 24 | — | $472.0M | ||
| Q3 24 | — | $493.0M | ||
| Q2 24 | — | $144.0M |
总资产DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | $4.0B | $12.9B | ||
| Q3 25 | $3.9B | $13.6B | ||
| Q2 25 | $3.9B | $13.5B | ||
| Q1 25 | — | $13.2B | ||
| Q4 24 | — | $13.1B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $12.2B |
负债/权益比DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | — | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | — | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $290.3M | — |
| 自由现金流经营现金流 - 资本支出 | $262.9M | — |
| 自由现金流率自由现金流/营收 | 32.1% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | 3.47× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | $290.3M | $141.0M | ||
| Q3 25 | $246.1M | $264.0M | ||
| Q2 25 | $251.4M | $220.0M | ||
| Q1 25 | — | $75.0M | ||
| Q4 24 | — | $390.0M | ||
| Q3 24 | — | $141.0M | ||
| Q2 24 | — | $332.0M |
自由现金流DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | $262.9M | $96.0M | ||
| Q3 25 | $217.6M | $218.0M | ||
| Q2 25 | $227.8M | $181.0M | ||
| Q1 25 | — | $43.0M | ||
| Q4 24 | — | $335.0M | ||
| Q3 24 | — | $99.0M | ||
| Q2 24 | — | $300.0M |
自由现金流率DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | 32.1% | 6.4% | ||
| Q3 25 | 27.2% | 13.6% | ||
| Q2 25 | 29.8% | 11.4% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | — | 6.3% | ||
| Q2 24 | — | 18.7% |
资本支出强度DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | 3.0% | ||
| Q3 25 | 3.6% | 2.9% | ||
| Q2 25 | 3.1% | 2.4% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 2.0% |
现金转化率DOCUOGN
| Q1 26 | — | — | ||
| Q4 25 | 3.47× | — | ||
| Q3 25 | 3.91× | 1.65× | ||
| Q2 25 | 3.49× | 1.52× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 1.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCU
| Subscription And Circulation | $801.0M | 98% |
| Professional Services And Other | $17.4M | 2% |
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
